Skip to content

Does exercise change how many immune cells are in the blood during different stages of myeloma?

Characterising the effects of exercise on immune cells in blood across the myeloma survivorship continuum

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN10197225
Enrollment
45
Registered
2021-07-08
Start date
2022-01-01
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma Cancer Multiple myeloma

Interventions

This study will investigate if an acute, 30-minute bout of static cycling can temporarily increase the number of immune cells in the blood and if exercise can improve the way anti-cancer treatments wo

Sponsors

University of Bath
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. A diagnosis of smouldering multiple myeloma who have not received any treatment. 2. A diagnosis of multiple myeloma who have either: completed their first cycle of induction therapy, or are in remission following a successful haematopoietic stem cell transplant. 3. Aged 18 years or over.

Exclusion criteria

Exclusion criteria: 1. World Health Organisation (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status >1. 2. Deemed unsafe to exercise according to the Physical Activity Readiness Questionnaire (PARQ). 3. Any comorbidity that is likely to progress or be exacerbated over the course of the trial period. 4. Cognitive impairment deemed a risk by the healthcare team or participation in the trials (e.g. diagnosis of neurodegenerative disease). 5. Unable to understand explanations and/or provide informed consent. 6. Any condition and/or behaviour that would pose undue personal risk or introduce bias into the trial.

Design outcomes

Primary

MeasureTime frame
The frequency of NK cells, T cells and monocytes in the blood will be measured using flow cytometry before exercise, immediately after exercise, and 30-minutes after exercise.

Secondary

MeasureTime frame
1. The frequency of polyclonal and clonotypic B cells will be measured using flow cytometry before exercise, immediately after exercise, and 30-minutes after exercise. 2. The cytotoxicity of NK cells will be measured using ex vivo assay models before exercise, immediately after exercise, and 30-minutes after exercise. 3. The efficacy of anti-myeloma therapies against a myeloma tumour cell line will be measured using ex vivo assay models before exercise, immediately after exercise, and 30-minutes after exercise.

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026